(Rac) -Cemsidomide

(Rac) -Cemsidomide ((Rac) -CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity[1]. Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.

Product Specifications

CAS Number

[2504233-68-3]

Product Name Alternative

(Rac) -CFT7455

UNSPSC

12352005

Target

Molecular Glues

Type

Reference compound

Related Pathways

PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rac-cemsidomide.html

Concentration

10mM

Purity

98.52

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1N(C2C(NC(CC2)=O)=O)C3=CC=C(C4=CC=CC1=C43)CC5=CC=C(C=C5)CN6CCOCC6

Molecular Formula

C28H27N3O4

Molecular Weight

469.53

References & Citations

[1]David Proia et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1 (compound 5) |[2]James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement) : LB007.